TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00000250

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% N2O
Description: Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Description: Subjects will inhale 40% N2O then immerse forearm in warm water and cold water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Description: Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
Study: NCT04570488

Intervention type: OTHER
Intervention: EPIC risk score display
Description: Display of risk score/ colored flag in Epic patient list column
Study: NCT03869307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
Study: NCT02633592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HRARM
Description: Patients and healthy volunteers are investigated in the seated and lying position during HRAM
Study: NCT00603798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod cream
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod cream
Description: 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
Study: NCT03048604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genio(TM) bilateral hypoglossal nerve stimulation system
Description: Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
Study: NCT01412385

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human), 20%
Description: Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human), 20%
Description: Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human), 10%
Description: Intravenous infusion (regulated via a pump)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Description: Subcutaneous infusion (regulated via a pump)
Study: NCT02343705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Latella Knee Implant System
Study: NCT02133807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific Lp(a) apheresis
Description: Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol
Study: NCT02103413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-BD
Description: When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTBD
Description: PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
Study: NCT03147989

Intervention type: DRUG
Intervention: MultiHance
Description: gadolinium contrast agent

Intervention type: DRUG
Intervention: MultiHance
Description: gadolinium contrast agent
Study: NCT04546542

Intervention type: OTHER
Intervention: Parallel Assignment
Description: We will evaluate 75 patients with pSS (Consenso Americano-europeu de 2002 / EULAR/ACR Classification Criteria, 2016) of both sexes at baseline and 6-months
Study: NCT01124981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haemocomplettan® P
Description: Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human albumin (Placebo)
Description: Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
Study: NCT04320108

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy 6 times during 2 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy 6 times during 2 weeks
Study: NCT03809910

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Reference MTB
Description: Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference PTB
Description: Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype PTB (Gum line mode)
Description: Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff.
Study: NCT05656456

Intervention type: OTHER
Intervention: Y-BOCS or FAS online survey, interview
Description: Y-BOCS or FAS and online survey will be administered interview will be conducted

Intervention type: OTHER
Intervention: Y-BOCS or FAS online survey, interview
Description: Y-BOCS or FAS and online survey will be administered interview will be conducted
Study: NCT03884478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Personalized Normative Feedback
Description: Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
Study: NCT02486939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-0214
Description: Open label
Study: NCT00164021

Intervention type: PROCEDURE
Intervention: Physiotherapy, exercise, percutaneous gastrostomy feeds

Intervention type: DRUG
Intervention: Anti-reflux pharmacotherapy
Study: NCT03618888

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructor-led training
Description: The Instructor-led training contents a supervised practical training with a standard kit for training in BLS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-learning training
Description: The self-learning training contents a standard kit for self-directed training in BLS
Study: NCT00785031

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: internet based vascular risk factor intervention
Description: The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54175446
Description: Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
Study: NCT01466569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn-7
Description: Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Study: NCT01142063

Intervention type: DRUG
Intervention: Neratinib
Description: Tablet, a 240 mg single oral dose

Intervention type: DRUG
Intervention: Neratinib
Description: Tablet, a 240 mg single oral dose

Intervention type: DRUG
Intervention: Neratinib
Description: Tablet, a 240 mg single oral dose

Intervention type: DRUG
Intervention: Neratinib
Description: Tablet, a 240 mg single oral dose
Study: NCT04207372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein isolate
Description: whey protein isolate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zein
Description: zein protein

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: protein-free
Description: protein free
Study: NCT01630668

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: One-a-Day L. reuteri NCIMB 30242 supplement capsule
Description: Once per day, 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: One-a-Day placebo capsule
Description: Once per day, 12 weeks
Study: NCT03233542

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behaviour Therapy
Description: Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy
Description: Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
Study: NCT01544907

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PTA
Description: Use of conventional balloon for angioplasty only

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon (DEB)
Description: Use of DEB after conventional balloon angioplasty
Study: NCT04884191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Pacritinib
Study: NCT03133299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Oral prednisolone for four months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Oral prednisolone for four months
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.
Study: NCT03133299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral vitamin D for two months
Study: NCT03556410

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: sleep
Description: Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep
Description: Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
Study: NCT01849523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based information and support
Study: NCT01762982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.13% Benzalkonium Chloride
Description: Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SLS Solution
Description: Finn Chamber filled with SLS (0.3% w/v) water solution
Study: NCT02515955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Participants will receive minocycline 100 mg as capsule twice daily.
Study: NCT01762982

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Water
Description: Finn Chamber filled with Normal Saline water (0.9% w/v)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Empty Finn Chamber
Description: Empty Finn Chamber
Study: NCT01966705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form.
Study: NCT00516399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone-iodine 1.25% ophthalmic solution
Study: NCT02633592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI Defecography
Description: Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
Study: NCT00321191

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No nitrous oxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of N2O
Study: NCT03442439

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Play Intervention
Description: Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
Study: NCT03298217

Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of the peak tidal inspiratory flow (PTIF)
Description: In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF).
Study: NCT03261011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK-104
Description: Subjects will receive AK104 by intravenous administration.
Study: NCT00365703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feeding tube insertion
Description: 1. Orogastric feeding tube~2. Nasogastric feeding tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feeding tube insertion
Description: 1. Orogastric feeding tube~2. Nasogastric feeding tube
Study: NCT00948155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
Study: NCT00516399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natamycin ophthalmic suspension, USP 5%
Study: NCT04453488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® vaccine
Description: Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological serum, 0.9% NaCl, will be used as a placebo
Study: NCT03809910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype PTB (Combined mode)
Description: Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff.
Study: NCT03223623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TMS
Description: Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VASO Imaging
Description: The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VASO Imaging
Description: The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
Study: NCT02913768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT01765725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education program
Description: Patient education program, 8 meetings, every other week, 2,5 hours per meeting.